Back to Results
First PageMeta Content
Pharmacology / Discovery and development of tubulin inhibitors / Basilea Pharmaceutica / Medicine / Angiogenesis


PRESS RELEASE Basilea’s oncology drug candidate BAL101553 shows first evidence of antitumor activity in phase 1 study  Results of recently completed clinical phase 1 study presented at ASCO
Add to Reading List

Document Date: 2014-06-23 09:59:40

Open Document

File Size: 37,41 KB

Share Result on Facebook

City

Basel / Chicago / /

Company

Basilea Pharmaceutica International Ltd. / Basilea Basilea Pharmaceutica Ltd. / Basilea Pharmaceutica Ltd. / 2 Basilea Pharmaceutica Ltd. / /

Country

Switzerland / United States / /

/

Event

FDA Phase / /

IndustryTerm

Cancer Therapeutics / pharmaceutical products / /

MedicalCondition

tumor / Cancer / bacterial infections / advanced solid tumors / nausea / selected solid tumor / peripheral neuropathy / well-manageable / transient hypertension / vomiting / preclinical cancer / numerous drug-refractory tumor / stable disease / pre-treatment tumor / diarrhea / drug refractory breast cancers / fungal infections / /

MedicalTreatment

intravenous infusion / /

Organization

American Association of Cancer Research / American Society of Clinical Oncology / /

Person

Achim Kaufhold / Nils Schröder / Barbara Zink / /

/

Position

Chief Medical Officer / PhD Head Corporate Development Head Public Relations & Corporate Communications / /

Product

BAL101553 / BAL27862 / /

PublishedMedium

Cancer Research / /

Technology

pharmacokinetics / pharmacodynamics / /

URL

http /

SocialTag